DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $779,064 | -71.3% | 26,400 | -77.6% | 0.00% | -71.4% |
| Q1 2023 | $2,716,416 | -35.7% | 117,900 | -22.3% | 0.01% | -41.7% |
| Q4 2022 | $4,221,558 | -25.2% | 151,800 | -17.4% | 0.01% | -25.0% |
| Q3 2022 | $5,641,000 | +19.4% | 183,800 | +14.5% | 0.02% | +23.1% |
| Q2 2022 | $4,724,000 | -14.7% | 160,500 | -6.8% | 0.01% | -13.3% |
| Q1 2022 | $5,540,000 | -53.9% | 172,200 | -36.1% | 0.02% | -50.0% |
| Q4 2021 | $12,024,000 | -43.4% | 269,600 | -36.0% | 0.03% | -45.5% |
| Q3 2021 | $21,244,000 | -41.6% | 421,100 | -9.3% | 0.06% | -42.7% |
| Q2 2021 | $36,404,000 | +41.3% | 464,100 | +2.8% | 0.10% | +35.2% |
| Q1 2021 | $25,769,000 | +17.8% | 451,300 | +72.8% | 0.07% | +22.4% |
| Q4 2020 | $21,870,000 | +910.6% | 261,100 | +332.3% | 0.06% | +866.7% |
| Q3 2020 | $2,164,000 | +633.6% | 60,400 | +395.1% | 0.01% | +500.0% |
| Q2 2020 | $295,000 | – | 12,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |